Compensation for Chemotherapy Patients Who Have Experienced Persistent Thinning or Spotty Hair Loss

According to documents filed in current litigation, the company sought to bury the risk of permanent hair loss in breast cancer patients to increase sales, a scheme that had a real impact on health outcomes. Many patients were never told about the less-expensive, equally effective alternative drug, Taxol. A study shows that women who received the less expensive drug, Taxol, had a higher survival rate than women who were treated with Taxotere.

While temporary hair loss is a recognized and accepted side effect of chemotherapy treatments, permanent baldness and persistent thinning hair should not be when there are options that are as effective or more effective with less severe side effects. This information should have been made available to women and their doctors so they could have made a more informed choice.


Why are Women Filing Lawsuits Against the Maker or Taxotere?

Lawsuits filed against Sanofi-Aventis, the manufacturer and marketer of Taxotere claim numerous legal actions against the drug maker that include:

  • Selling the drug without adequately testing it
  • Failing to determine whether the drug was safe for use
  • Selling and marketing the drug without disclosing the dangers or risks
  • Failing to properly warn patients and health care providers even though they allegedly knew of the risks
  • Misleading the public and doctors in advertising and marketing campaigns
  • Manufacturing a dangerous drug
  • Concealing information from the public and medical professionals
  • Downplaying the dangers associated with the drug

Permanent Hair Loss Lawsuit Information

"According to a study published by the National Cancer Research Institute (NCRI) in 2013, 10-15% of patients who take Taxotere experience permanent or persistent hair loss as a side effect of the chemotherapy medication."

Taxotere is a synthetic chemotherapy drug often used to treat breast cancer. It was falsely promoted by its manufacturer, Sanofi-Aventis, as a more effective treatment option than the already established chemotherapy drug Taxol.

As a later to market drug, the Sanofi-Aventis sales team illegally pushed inaccurate marketing material to doctors and other medical decision makers stating that their drug was more effective than Taxol even though it was actually equally effective at best. The FDA later stated it was not more effective than their competitor Taxol and subsequently sent Sanofi-Aventis a letter reprimanding them for their unethical and illegal business practices.

Sanofi-Aventis also intentionally failed to warn doctors and women about the risk of permanent hair loss associated with this drug even though they were aware of this devastating side effect as early as 2002 and very likely earlier.

Additional Taxotere Resources

Rate This Service

5/5 - (5 votes)

Did you or a loved one suffer permanent or persistent hair loss following chemotherapy?

Find out if you may qualify for compensation.

Find Out More
Copyright © 2016-2017 Consumer Safety Watch. All Rights Reserved. Privacy / Terms / Disclaimer

Consumer Safety Watch offers safety advocate services and attorney referral services for patients throughout the United States including the states of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.

Consumer Safety Watch offers consumer safety advocate services or can help you find an attorney throughout the United States including the following cities: Albuquerque, NM; Arlington, TX; Atlanta, GA; Austin, TX; Baltimore, MD; Boston, MA; Charlotte, NC; Chicago, IL; Cleveland, OH; Colorado Springs, CO; Columbus, OH; Dallas, TX; Denver, CO; Detroit, MI; Fresno, CA; Fort Worth, TX; Indianapolis, IN; Honolulu, HI; Houston, TX; Jacksonville, FL; Kansas City, KS; Kansas City, MO; Las Vegas, NV; Long Beach, CA; Los Angeles, CA; Louisville, KY; Memphis, TN; Mesa, AZ; Miami, FL; Miami, OH; Milwaukee, WI; Minneapolis, MN; Nashville, TN; New York City, NY; Oakland, CA; Oklahoma City, OK; Omaha, NE; Philadelphia, PA; Phoenix, AZ; Pittsburgh, PA; Portland, OR; Sacramento, CA; San Antonio, Tx; San Diego, CA; San Francisco, CA; San Jose, CA; Seattle, WA; St. Louis, MO; Tampa, FL; Tucson, AZ; Tulsa, Virginia Beach, VA; Washington, DC; Wichita, KS.